NCT05204290
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Bone
Additional Notes: Patients must be deemed eligible for stereotactic body radiation therapy & pembrolizumab
Exclusions: Patients with symptomatic brain metastases
https://ClinicalTrials.gov/show/NCT05204290